Alvin Wee
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Alvin Wee has a total of 75 co-authors. Here are the top co-authors by number of shared publications:
- Emilio D. Poggio
Cleveland Clinic Foundation, Cleveland, Ohio, USA
6 shared publications - Mohamed Eltemamy
Department of Urology, Glickman Urological and Kidney Institute, Cleveland Clinic, Cleveland, USA
6 shared publications - Christine E. Koval
Department of Infectious Disease Cleveland Clinic Cleveland Ohio USA
4 shared publications - Jesse D. Schold
Department of Surgery, University of Colorado Anschutz Medical Campus, Aurora, CO
3 shared publications - Joshua J. Augustine
Cleveland Clinic, Cleveland, Ohio
3 shared publications - Anthony Chang
University of Chicago
2 shared publications
Latest Publications
- Open Access
- 16 July 2026
- Published by Wiley in Transplant Infectious Disease
- Vol. 28 (5) , e70278
Early Onset Bacteremia in Kidney Transplant Recipients in the Current Era
Background: Bloodstream infection (BSI) after kidney transplantation increases the risk of graft loss and mortality. We aimed to identify contemporary risk factors and outcomes of early BSI (eBSI) at our transplant center. Methods: We conducted a retrospective chart review of adult kidney transplant recipients (KTRs) from 2019 to 2023. Those with the eBSI (within 90 days of KTR) were matched by age and gender to controls. Risk factors were identified using multivariable logistic regression. All KTRs surviving to 90 days, were included in graft and patient survival analysis. Results: Among 1408 KTRs, 75 (5.3%) developed eBSI, at a median of 21 days (IQR: 12–42.5). On multivariable analysis, each doubling of hospital duration was independently associated with a 49% increase in the risk of eBSI (OR: 1.49, 95% CI: 1.19–1.91; p < 0.001), and each doubling of postsurgical drain retention duration was independently associated with a 68% increase in the risk of eBSI (OR: 1.68, 95% CI: 1.17–2.48; p 0.006). eBSI was associated with 1‐year mortality (aHR: 3.32, 95% CI: 1.51–7.28; p 0.003) and 3‐year graft failure (aHR: 2.78, 95% CI: 1.31–5.93; p 0.008). Conclusion: eBSI was associated with graft failure and mortality. The donor and recipient factors identified highlight the need for further studies to better characterize their impact on eBSI.
- 16 July 2026
- Published by Wiley in Transplant Infectious Disease
- Vol. 28 (5) , e70278
Open AccessEarly Onset Bacteremia in Kidney Transplant Recipients in the Current Era
Background: Bloodstream infection (BSI) after kidney transplantation increases the risk of graft loss and mortality. We aimed to identify contemporary risk factors and outcomes of early BSI (eBSI) at our transplant center. Methods: We conducted a retrospective chart review of adult kidney transplant recipients (KTRs) from 2019 to 2023. Those with the eBSI (within 90 days of KTR) were matched by age and gender to controls. Risk factors were identified using multivariable logistic regression. All KTRs surviving to 90 days, were included in graft and patient survival analysis. Results: Among 1408 KTRs, 75 (5.3%) developed eBSI, at a median of 21 days (IQR: 12–42.5). On multivariable analysis, each doubling of hospital duration was independently associated with a 49% increase in the risk of eBSI (OR: 1.49, 95% CI: 1.19–1.91; p < 0.001), and each doubling of postsurgical drain retention duration was independently associated with a 68% increase in the risk of eBSI (OR: 1.68, 95% CI: 1.17–2.48; p 0.006). eBSI was associated with 1‐year mortality (aHR: 3.32, 95% CI: 1.51–7.28; p 0.003) and 3‐year graft failure (aHR: 2.78, 95% CI: 1.31–5.93; p 0.008). Conclusion: eBSI was associated with graft failure and mortality. The donor and recipient factors identified highlight the need for further studies to better characterize their impact on eBSI.
- 19 May 2026
- Published by Elsevier in Endocrine Practice
- Vol. 32 (10) , 1483-1487
Continuous Glucose Monitoring for Postkidney Transplantation in Patient With Pre-existing Type 2 Diabetes
- 19 May 2026
- Published by Elsevier in Endocrine Practice
- Vol. 32 (10) , 1483-1487
Continuous Glucose Monitoring for Postkidney Transplantation in Patient With Pre-existing Type 2 Diabetes
- Open Access
- 14 May 2026
- Published by Wolters Kluwer Health in Kidney360
- Vol. 7 (8) , 1792-1806
A Pre-Kidney Transplant Blood-Based Next-Generation Sequencing Assay to Predict Early Acute Rejection
Key Points: Pretransplant early acute rejection risk stratification offers a novel approach to personalized immunosuppression management in patients who received a kidney transplant. Stratifying immunologic risk independent of donor characteristics may help guide immunosuppression management in patients who received a kidney transplant. The pretransplant risk assessment gene set reflects metabolic and immune pathways involved in T-cell– and antibody-mediated mechanisms of transplant rejection. Background: Although donor and recipient characteristics are used to estimate graft failure risk, they remain limited in predicting early acute rejection (EAR). We developed and validated a next-generation sequencing assay targeting the pretransplant immunologic profile to predict EAR following kidney transplantation. Methods: This prospective, international study enrolled 321 kidney transplant participants across 13 sites, forming discovery and validation cohorts. Peripheral blood was collected before transplant and at 1, 3, 6, 12, and 24 months post-transplant, with protocol biopsies performed at 3 and 12 months, as well as any indication biopsies. Biopsies were assessed by a blinded central pathologist according to the 2019 Banff criteria. The pretransplant risk assessment (PTRA) test to evaluate RNA expression of a 29-gene signature algorithm designed to predict EAR risk was clinically validated using 122 deceased donor kidney transplant recipients. Results: PTRA classified 31 of 122 participants (25%) as high risk and 91 (75%) as low risk. There were nine EAR events in the first 60 days post-transplant: 6/31 (19%) in the high-risk group and 3/91 (3%) in the low-risk group. PTRA discrimination for EAR at 60 days post-transplant yielded an area under the curve of 0.78 (95% confidence interval [CI], 64.4 to 91.5), P < 0.001. A cutoff of ≤45 was defined as low risk and >45 as high risk for EAR within 60 days post-transplant. Sensitivity was 0.67 (95% CI, 0.36 to 0.97), specificity 0.78 (95% CI, 0.70 to 0.86), positive predictive value 0.19 (95% CI, 0.05 to 0.33), and negative predictive value 0.97 (95% CI, 0.93 to 1.00). The odds ratio comparing patients identified as high versus low risk by PTRA was 7.04 (95% CI, 1.64 to 30.2), P = 0.009. Conclusions: This study validates the ability of PTRA to stratify kidney transplant recipients as high or low risk for EAR using a pretransplant transcriptomic profile, with implications for graft health and personalized treatment management.
- 14 May 2026
- Published by Wolters Kluwer Health in Kidney360
- Vol. 7 (8) , 1792-1806
Open AccessA Pre-Kidney Transplant Blood-Based Next-Generation Sequencing Assay to Predict Early Acute Rejection
Key Points: Pretransplant early acute rejection risk stratification offers a novel approach to personalized immunosuppression management in patients who received a kidney transplant. Stratifying immunologic risk independent of donor characteristics may help guide immunosuppression management in patients who received a kidney transplant. The pretransplant risk assessment gene set reflects metabolic and immune pathways involved in T-cell– and antibody-mediated mechanisms of transplant rejection. Background: Although donor and recipient characteristics are used to estimate graft failure risk, they remain limited in predicting early acute rejection (EAR). We developed and validated a next-generation sequencing assay targeting the pretransplant immunologic profile to predict EAR following kidney transplantation. Methods: This prospective, international study enrolled 321 kidney transplant participants across 13 sites, forming discovery and validation cohorts. Peripheral blood was collected before transplant and at 1, 3, 6, 12, and 24 months post-transplant, with protocol biopsies performed at 3 and 12 months, as well as any indication biopsies. Biopsies were assessed by a blinded central pathologist according to the 2019 Banff criteria. The pretransplant risk assessment (PTRA) test to evaluate RNA expression of a 29-gene signature algorithm designed to predict EAR risk was clinically validated using 122 deceased donor kidney transplant recipients. Results: PTRA classified 31 of 122 participants (25%) as high risk and 91 (75%) as low risk. There were nine EAR events in the first 60 days post-transplant: 6/31 (19%) in the high-risk group and 3/91 (3%) in the low-risk group. PTRA discrimination for EAR at 60 days post-transplant yielded an area under the curve of 0.78 (95% confidence interval [CI], 64.4 to 91.5), P < 0.001. A cutoff of ≤45 was defined as low risk and >45 as high risk for EAR within 60 days post-transplant. Sensitivity was 0.67 (95% CI, 0.36 to 0.97), specificity 0.78 (95% CI, 0.70 to 0.86), positive predictive value 0.19 (95% CI, 0.05 to 0.33), and negative predictive value 0.97 (95% CI, 0.93 to 1.00). The odds ratio comparing patients identified as high versus low risk by PTRA was 7.04 (95% CI, 1.64 to 30.2), P = 0.009. Conclusions: This study validates the ability of PTRA to stratify kidney transplant recipients as high or low risk for EAR using a pretransplant transcriptomic profile, with implications for graft health and personalized treatment management.
- Open Access
- 13 March 2026
- Published by Wiley in Transplant Infectious Disease
- Vol. 28 (4) , e70202
Comparative 3‐Year Allograft Outcomes for Recipients of Kidneys From SARS‐CoV‐2 NAT‐Positive Donors
Background: Data demonstrates safety and short‐term success of kidney transplantation (KT) from SARS‐CoV‐2 NAT‐positive organ donors (NAT+) compared to NAT‐negative donors. However, detailed reports of longer‐term graft outcomes are limited and lack granular data on donor SARS‐CoV‐2 infection severity. Methods: We retrospectively reviewed records from 220 recipients of KT (KTRs) at our institution from February 1, 2021, to January 31, 2022. We compared 1‐ and 3‐year allograft‐specific outcomes for KTRs from NAT+ ( N = 59), CoV‐COD (COVID as cause of death) ( N = 56), and NAT‐neg ( N = 105) donors. We reviewed and compared pathology findings for allograft biopsies for all groups up to 1 year. We examined the association of eGFR at 3 years with CoV‐donor status using multivariable linear regression. Results: At 1 year, there was no difference in rejection or kidney pathologies by CoV‐donor status. At 3 years, there was no difference in patient death or graft loss by group. For subjects without graft loss, eGFR at 3 years for NAT+, CoV‐COD, and NAT‐neg donors was 54.8 (21.8), 45.6(17.9), and 48.4 (23.3) mL/min/m 2 , respectively ( p = 0.61). On multivariable analysis, there was no significant association of eGFR with CoV‐donor status. Conclusions: We found no significant difference in pathological findings or 3‐year allograft outcomes following KT from NAT‐negative, NAT+, or CoV‐COD donors. Despite modestly reduced eGFR for COV‐COD on unadjusted analysis, kidneys from donors with a spectrum of COVID severities did not experience significantly poorer allograft outcomes over 3 years. image
- 13 March 2026
- Published by Wiley in Transplant Infectious Disease
- Vol. 28 (4) , e70202
Open AccessComparative 3‐Year Allograft Outcomes for Recipients of Kidneys From SARS‐CoV‐2 NAT‐Positive Donors
Background: Data demonstrates safety and short‐term success of kidney transplantation (KT) from SARS‐CoV‐2 NAT‐positive organ donors (NAT+) compared to NAT‐negative donors. However, detailed reports of longer‐term graft outcomes are limited and lack granular data on donor SARS‐CoV‐2 infection severity. Methods: We retrospectively reviewed records from 220 recipients of KT (KTRs) at our institution from February 1, 2021, to January 31, 2022. We compared 1‐ and 3‐year allograft‐specific outcomes for KTRs from NAT+ ( N = 59), CoV‐COD (COVID as cause of death) ( N = 56), and NAT‐neg ( N = 105) donors. We reviewed and compared pathology findings for allograft biopsies for all groups up to 1 year. We examined the association of eGFR at 3 years with CoV‐donor status using multivariable linear regression. Results: At 1 year, there was no difference in rejection or kidney pathologies by CoV‐donor status. At 3 years, there was no difference in patient death or graft loss by group. For subjects without graft loss, eGFR at 3 years for NAT+, CoV‐COD, and NAT‐neg donors was 54.8 (21.8), 45.6(17.9), and 48.4 (23.3) mL/min/m 2 , respectively ( p = 0.61). On multivariable analysis, there was no significant association of eGFR with CoV‐donor status. Conclusions: We found no significant difference in pathological findings or 3‐year allograft outcomes following KT from NAT‐negative, NAT+, or CoV‐COD donors. Despite modestly reduced eGFR for COV‐COD on unadjusted analysis, kidneys from donors with a spectrum of COVID severities did not experience significantly poorer allograft outcomes over 3 years. image
- 5 December 2025
- Published by Wolters Kluwer Health in Clinical Journal of the American Society of Nephrology
- Vol. 21 (4) , 641-649
Outcomes of Deceased Donor Kidney Transplants Allocated Out of Sequence in the United States
Key Points: We used national data to examine the outcomes of kidney transplant allocated as out of sequence offers to transplant centers in the United States. Short-term kidney graft failure does not differ between kidneys that were allocated as out of sequence offers versus standard allocation. Background: Changes in kidney allocation policies and regulations of Organ Procurement Organizations have affected the volume of organ offers and challenged transplant providers. One consequence is increased kidneys allocated out of sequence (OOS). Methods: Retrospective observational study using Scientific Registry of Transplant Recipient data from 2021 to 2023, we analyzed donor and recipient characteristics for OOS versus standard kidney allocation and multivariable Cox models to evaluate graft survival. We also compared paired donors (one kidney OOS and the other standard allocation). Results: Annual OOS kidney allocation rates increased from 5.4% in 2021 to 18.4% in 2023. High OOS-use centers increased from 5 (2.2%) between 2021 and June 2022 to 37 (17%) in 2023. Listing at a high-OOS usage center was associated with increased rate of deceased donor transplantation (adjusted hazard ratio [AHR], 3.07; 95% confidence interval [CI], 2.90 to 3.25). Recipients of OOS allocation were more likely to be male (66% versus 59%), White race (38% versus 32%), privately insured (29% versus 24%), and preemptively transplanted (18% versus 10%). Overall graft loss was not significantly different between OOS and standard allocated transplants (AHR, 0.94; 95% CI, 0.85 to 1.05), consistent in paired donor analysis (AHR, 1.10; 95% CI, 0.86 to 1.41). Conclusions: Short-term kidney graft failure does not differ between OOS and standard allocation. High-OOS kidney centers have higher deceased donor transplant rates. Further investigation is needed to understand demographic differences and factors explaining OOS allocation.
- 5 December 2025
- Published by Wolters Kluwer Health in Clinical Journal of the American Society of Nephrology
- Vol. 21 (4) , 641-649
Outcomes of Deceased Donor Kidney Transplants Allocated Out of Sequence in the United States
Key Points: We used national data to examine the outcomes of kidney transplant allocated as out of sequence offers to transplant centers in the United States. Short-term kidney graft failure does not differ between kidneys that were allocated as out of sequence offers versus standard allocation. Background: Changes in kidney allocation policies and regulations of Organ Procurement Organizations have affected the volume of organ offers and challenged transplant providers. One consequence is increased kidneys allocated out of sequence (OOS). Methods: Retrospective observational study using Scientific Registry of Transplant Recipient data from 2021 to 2023, we analyzed donor and recipient characteristics for OOS versus standard kidney allocation and multivariable Cox models to evaluate graft survival. We also compared paired donors (one kidney OOS and the other standard allocation). Results: Annual OOS kidney allocation rates increased from 5.4% in 2021 to 18.4% in 2023. High OOS-use centers increased from 5 (2.2%) between 2021 and June 2022 to 37 (17%) in 2023. Listing at a high-OOS usage center was associated with increased rate of deceased donor transplantation (adjusted hazard ratio [AHR], 3.07; 95% confidence interval [CI], 2.90 to 3.25). Recipients of OOS allocation were more likely to be male (66% versus 59%), White race (38% versus 32%), privately insured (29% versus 24%), and preemptively transplanted (18% versus 10%). Overall graft loss was not significantly different between OOS and standard allocated transplants (AHR, 0.94; 95% CI, 0.85 to 1.05), consistent in paired donor analysis (AHR, 1.10; 95% CI, 0.86 to 1.41). Conclusions: Short-term kidney graft failure does not differ between OOS and standard allocation. High-OOS kidney centers have higher deceased donor transplant rates. Further investigation is needed to understand demographic differences and factors explaining OOS allocation.
- 31 December 2024
- Published by Wiley in Clinical Transplantation
- Vol. 39 (1) , e70056
Implementation of a Comprehensive Protocol for Enhanced Recovery After Surgery (ERAS) in Kidney Transplant Recipients Improves Patient and Graft Outcomes
Background: Enhanced recovery after surgery (ERAS) protocols have gained widespread acceptance as a means to enhance surgical outcomes. However, the intricate care required for kidney transplant recipients has not yet led to the establishment of a universally recognized and dependable ERAS protocol for kidney transplantation.Objective: We devised a customized ERAS protocol to determine its effectiveness in improving surgical and postoperative outcomes among kidney transplant recipients.Design, Setting, and Participants: This was a retrospective, single‐center study performed at our tertiary care institution. Three hundred and fifty‐six patients in the conventional group (from January 1, 2015 to December 31, 2017) and 442 patients from the ERAS group (from January 1, 2018 to June 1, 2020) were compared. Patients were followed for 1 year postoperatively.Intervention: Changes were made in the preoperative, operative, postoperative, and outpatient follow‐up settings after transplantation.Outcome Measurements and Statistical Analysis: Primary endpoints were hospital length of stay (LOS) and 30‐day readmission rates. We also measured surgical outcomes, graft performance, and patient survival. Wilcoxon rank‐sum, Pearson's Chi‐squared, or Fisher's exact tests were used to compare groups.Results: Our ERAS protocol was associated with a decrease in hospital LOS from 5 to 3 days (p < 0.001) and 57.1% lower odds of hospital readmissions within 30 days compared to the conventional group (p < 0.001, 95% CI 0.26–0.7). Decreases in operative estimated blood loss, blood transfusion rates, and delayed graft function were also associated with the ERAS protocol.Conclusion: Our multi‐layered ERAS protocol is effective in improving outcomes for kidney transplant recipients. A future multi‐institutional study with healthcare savings analysis may suggest that widespread benefits are yet to be realized by the greater implementation of such enhanced recovery protocols.
- 31 December 2024
- Published by Wiley in Clinical Transplantation
- Vol. 39 (1) , e70056
Implementation of a Comprehensive Protocol for Enhanced Recovery After Surgery (ERAS) in Kidney Transplant Recipients Improves Patient and Graft Outcomes
Background: Enhanced recovery after surgery (ERAS) protocols have gained widespread acceptance as a means to enhance surgical outcomes. However, the intricate care required for kidney transplant recipients has not yet led to the establishment of a universally recognized and dependable ERAS protocol for kidney transplantation.Objective: We devised a customized ERAS protocol to determine its effectiveness in improving surgical and postoperative outcomes among kidney transplant recipients.Design, Setting, and Participants: This was a retrospective, single‐center study performed at our tertiary care institution. Three hundred and fifty‐six patients in the conventional group (from January 1, 2015 to December 31, 2017) and 442 patients from the ERAS group (from January 1, 2018 to June 1, 2020) were compared. Patients were followed for 1 year postoperatively.Intervention: Changes were made in the preoperative, operative, postoperative, and outpatient follow‐up settings after transplantation.Outcome Measurements and Statistical Analysis: Primary endpoints were hospital length of stay (LOS) and 30‐day readmission rates. We also measured surgical outcomes, graft performance, and patient survival. Wilcoxon rank‐sum, Pearson's Chi‐squared, or Fisher's exact tests were used to compare groups.Results: Our ERAS protocol was associated with a decrease in hospital LOS from 5 to 3 days (p < 0.001) and 57.1% lower odds of hospital readmissions within 30 days compared to the conventional group (p < 0.001, 95% CI 0.26–0.7). Decreases in operative estimated blood loss, blood transfusion rates, and delayed graft function were also associated with the ERAS protocol.Conclusion: Our multi‐layered ERAS protocol is effective in improving outcomes for kidney transplant recipients. A future multi‐institutional study with healthcare savings analysis may suggest that widespread benefits are yet to be realized by the greater implementation of such enhanced recovery protocols.
- Open Access
- 7 December 2023
- Published by Elsevier in American Journal of Transplantation
- Vol. 24 (3) , 436-447
Prospective observational study to validate a next-generation sequencing blood RNA signature to predict early kidney transplant rejection
- 7 December 2023
- Published by Elsevier in American Journal of Transplantation
- Vol. 24 (3) , 436-447
Open AccessProspective observational study to validate a next-generation sequencing blood RNA signature to predict early kidney transplant rejection
- Open Access
- 12 January 2023
- Published by Elsevier in American Journal of Transplantation
- Vol. 22 (12) , 2903-2911
Comparative outcomes for over 100 deceased donor kidney transplants from SARS-CoV-2 positive donors: A single-center experience
- 12 January 2023
- Published by Elsevier in American Journal of Transplantation
- Vol. 22 (12) , 2903-2911
Open AccessComparative outcomes for over 100 deceased donor kidney transplants from SARS-CoV-2 positive donors: A single-center experience
- Open Access
- 30 December 2022
- Published by Elsevier in American Journal of Transplantation
- Vol. 21 (11) , 3743-3749
Early success transplanting kidneys from donors with new SARS-CoV-2 RNA positivity: A report of 10 cases
- 30 December 2022
- Published by Elsevier in American Journal of Transplantation
- Vol. 21 (11) , 3743-3749
Open AccessEarly success transplanting kidneys from donors with new SARS-CoV-2 RNA positivity: A report of 10 cases
- Open Access
Ureter single-cell and spatial mapping reveal cell types, architecture, and signaling networks
Summary: Tissue engineering offers a promising treatment strategy for ureteral strictures, but its success requires an in-depth understanding of the architecture, cellular heterogeneity, and signaling pathways underlying tissue regeneration. Here we define and spatially map cell populations within the human ureter using single-cell RNA sequencing, spatial gene expression, and immunofluorescence approaches. We focused on the stromal and urothelial cell populations to enumerate distinct cell types composing the human ureter and inferred potential cell-cell communication networks underpinning the bi-directional crosstalk between these compartments. Furthermore, we analyzed and experimentally validated the importance of Sonic Hedgehog (SHH) signaling pathway in adult stem cell maintenance. The SHH -expressing basal cells supported organoid generation in vitro and accurately predicted the differentiation trajectory from basal stem cells to terminally differentiated umbrella cells. Our results highlight essential processes involved in adult ureter tissue homeostasis and provide a blueprint for guiding ureter tissue engineering.
Open AccessUreter single-cell and spatial mapping reveal cell types, architecture, and signaling networks
Summary: Tissue engineering offers a promising treatment strategy for ureteral strictures, but its success requires an in-depth understanding of the architecture, cellular heterogeneity, and signaling pathways underlying tissue regeneration. Here we define and spatially map cell populations within the human ureter using single-cell RNA sequencing, spatial gene expression, and immunofluorescence approaches. We focused on the stromal and urothelial cell populations to enumerate distinct cell types composing the human ureter and inferred potential cell-cell communication networks underpinning the bi-directional crosstalk between these compartments. Furthermore, we analyzed and experimentally validated the importance of Sonic Hedgehog (SHH) signaling pathway in adult stem cell maintenance. The SHH -expressing basal cells supported organoid generation in vitro and accurately predicted the differentiation trajectory from basal stem cells to terminally differentiated umbrella cells. Our results highlight essential processes involved in adult ureter tissue homeostasis and provide a blueprint for guiding ureter tissue engineering.